1.Comparison of Clinical Manifestations between Patients with Ocular Myasthenia Gravis and Generalized Myasthenia Gravis.
Hyun Seok ROH ; Sang Yeul LEE ; Jin Sook YOON
Korean Journal of Ophthalmology 2011;25(1):1-7
PURPOSE: To compare the clinical manifestations between patients with ocular myasthenia gravis and those with generalized myasthenia gravis (MG). METHODS: The medical records of 71 patients diagnosed with MG between January 1995 and December 2007 were reviewed. Demographics, sensitivities of diagnostic methods, the presence of systemic autoimmune diseases, ophthalmic complications caused by MG, and treatments were evaluated and compared. RESULTS: Fourteen patients (20%) were diagnosed with ocular MG and 57 patients (80%) with generalized MG. Sensitivities of anti-acetylcholine receptor antibody and repetitive nerve stimulation tests were significantly higher in the generalized MG group (84%, 89%) compared to those in the ocular MG group (50%, 54%) (p = 0.011, p = 0.008). The sensitivity of the neostigmine test was the highest in both groups (98% of generalized MG, 79% of ocular MG), and the difference between the two groups was borderline significant (p = 0.058). The most common symptoms were ptosis and diplopia, and both groups presented with pain, blurred vision, and tearing. Systemic autoimmune disease was more prominent in the generalized MG group (21%) than in the ocular MG group (14%), and steroid therapy was used more frequently in the generalized MG group (82%) than in the ocular MG group (57%). Ophthalmic complications associated with long-term steroid treatment were more profound in the generalized MG (30%) compared to those of the ocular MG (21%). CONCLUSIONS: The generalized MG group was associated with higher sensitivities to diagnostic tests, more systemic steroid use, higher ophthalmic complications caused by systemic autoimmune disease, and long-term steroid treatment compared to those of the ocular MG group.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Autoimmune Diseases/complications
;
Child
;
Drug Administration Schedule
;
Eye Diseases/chemically induced/immunology
;
Female
;
Humans
;
Male
;
Middle Aged
;
Myasthenia Gravis/complications/*diagnosis/*drug therapy
;
Steroids/*administration & dosage/adverse effects
;
Young Adult
2.Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Hyung Min KANG ; Myung Jin PARK ; Jeong Min HWANG ; Jin Wook KIM ; Sook Hyang JEONG
The Korean Journal of Hepatology 2009;15(2):209-215
A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal. The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin. The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.
Antiviral Agents/*adverse effects/therapeutic use
;
Drug Therapy, Combination
;
Hepatitis C, Chronic/complications/*drug therapy
;
Humans
;
Interferon Alfa-2b/*adverse effects/therapeutic use
;
Male
;
Middle Aged
;
Myasthenia Gravis/*chemically induced/*diagnosis
;
Polyethylene Glycols/*adverse effects/therapeutic use
;
Ribavirin/*adverse effects/therapeutic use